This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Compared to Estimates, Travere (TVTX) Q1 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Travere (TVTX) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Travere Therapeutics (TVTX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Travere (TVTX) delivered earnings and revenue surprises of 14.55% and 3%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Vertex Pharmaceuticals (VRTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
by Zacks Equity Research
Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Novavax (NVAX) Soars 11.4%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Novavax (NVAX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Compared to Estimates, Travere (TVTX) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Travere (TVTX) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Travere Therapeutics (TVTX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Travere (TVTX) delivered earnings and revenue surprises of -25.86% and 1.84%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Curious about Travere (TVTX) Q4 Performance? Explore Wall Street Estimates for Key Metrics
by Zacks Equity Research
Get a deeper insight into the potential performance of Travere (TVTX) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Travere Therapeutics (TVTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
Travere (TVTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Travere (TVTX) Moves 12.6% Higher: Will This Strength Last?
by Zacks Equity Research
Travere (TVTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Pacira (PCRX) Soars 11.1%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Pacira (PCRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Wall Street Analysts Believe Travere (TVTX) Could Rally 42.56%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 42.6% in Travere (TVTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Travere (TVTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
The headline numbers for Travere (TVTX) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Travere (TVTX) delivered earnings and revenue surprises of 0% and 4.10%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts See a 26.27% Upside in Travere (TVTX): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Travere (TVTX) points to a 26.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Travere (TVTX) Surges 11.6%: Is This an Indication of Further Gains?
by Zacks Equity Research
Travere (TVTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Travere (TVTX) Soars 5.9%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Travere (TVTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Travere Gains 11% on Securing Full FDA Nod for Kidney Disease Drug
by Zacks Equity Research
The approval expands the label of TVTX's Filspari in IgAN indication. However, the label also comes with a boxed warning for liver problems and congenital disabilities.
Here's What Key Metrics Tell Us About Travere (TVTX) Q2 Earnings
by Zacks Equity Research
While the top- and bottom-line numbers for Travere (TVTX) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Travere Therapeutics (TVTX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Travere (TVTX) delivered earnings and revenue surprises of -3.45% and 9.33%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Travere (TVTX): Can Its 8.8% Jump Turn into More Strength?
by Zacks Equity Research
Travere (TVTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Travere (TVTX) Stock Jumps 5.2%: Will It Continue to Soar?
by Zacks Equity Research
Travere (TVTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Ligand (LGND) Beats Q1 Earnings, Misses Sales Estimates
by Zacks Equity Research
Ligand Pharmaceuticals (LGND) reports mixed first-quarter results. Management reiterates the 2024 financial outlook.
Here's What Key Metrics Tell Us About Travere (TVTX) Q1 Earnings
by Zacks Equity Research
While the top- and bottom-line numbers for Travere (TVTX) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Travere Therapeutics (TVTX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Travere (TVTX) delivered earnings and revenue surprises of -79.59% and 2.70%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?